ERBB2 and neoplasm: To obtain more satisfactory outcomes with immunotherapy in HER2-positive breast cancer, reliable biomarkers and smart therapeutic strategies tailored to individual tumor biology and composite biomarkers are the most important factors, and our study can be used as a reference for planning these subsequent studies.